Recombinant EGFR (Zalutumumab Biosimilar) anticorps
Research Grade
Reactivité: Humain
ELISA
Hôte: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Antigène Tous les produits EGFR (Zalutumumab Biosimilar)
- EGFR (Zalutumumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
-
Mammalian Cells
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp EGFR (Zalutumumab Biosimilar) est non-conjugé
-
Application
- ELISA
- Fonction
- Zalutumumab Biosimilar - Anti-EGFR mAb
- Attributs du produit
- Antibody Type: IgG1-kappa
- Classe de qualité
- Research Grade
- Isotype
- IgG1 kappa
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Stock
- -80 °C
- Stockage commentaire
- store at -80°C
-
- Antigène
- EGFR (Zalutumumab Biosimilar)
- Abstract
- EGFR (Zalutumumab Biosimilar) Produits
- Synonymes
- anticorps ERBB, anticorps ERBB1, anticorps HER1, anticorps PIG61, anticorps mENA, anticorps epidermal growth factor receptor, anticorps EGFR
- Classe de substances
- Biosimilar
- Sujet
-
HuMax-EGFr
Zalutumumab (proposed trade name HuMax-EGFR) is a high affinity, completely human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR, also known as ErbB1/HER1). It is developed by Genmab and designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. Zalutumumab is derived from transgenic mice immunized with A431-derived EGFR. - Numéro CAS
- 667901-13-5
-
Vous êtes ici:
